Competitive Intelligence - EzySpot

Reliable. Secure. Since 2012. Exchange Crypto Sign up to get a trading fee discount!

Transform bandwidth into earnings with GetGrass

US FDA Clears HuidaGene’s HG202 IND Application for Innovative RNA-Editing Therapy for Neovascular AMD

US FDA Clears HuidaGene’s HG202 IND Application for Innovative RNA-Editing Therapy for Neovascular AMD thelansis.com

Thelansis knowledge Partners 1 year ago in Business 0

FDA Fast Tracks FELIQS’ FLQ-101 for Preventing Retinopathy of Prematurity (ROP)

FDA Fast Tracks FELIQS’ FLQ-101 for Preventing Retinopathy of Prematurity (ROP) thelansis.com

Thelansis knowledge Partners 1 year ago in Business 0

FDA Approves AbbVie’s VYALEV for 24-Hour Treatment of Advanced Parkinson’s Disease

FDA Approves AbbVie’s VYALEV for 24-Hour Treatment of Advanced Parkinson’s Disease thelansis.com

Thelansis knowledge Partners 1 year ago in Business 0

EMA Grants Orphan Drug Designation to NIDO-361 for Kennedy’s Disease

EMA Grants Orphan Drug Designation to NIDO-361 for Kennedy’s Disease thelansis.com

Thelansis knowledge Partners 1 year ago in Business 0

FDA Grants Orphan Drug Designation to Remedy Pharma’s CIRARA for Treatment of Acute Ischemic Stroke

FDA Grants Orphan Drug Designation to Remedy Pharma’s CIRARA for Treatment of Acute Ischemic Stroke thelansis.com

Thelansis knowledge Partners 1 year ago in Business 0

Sangamo Therapeutics Gains FDA Pathway to Accelerated Approval for ST-920 Gene Therapy in Fabry Disease Disease

Sangamo Therapeutics Gains FDA Pathway to Accelerated Approval for ST-920 Gene Therapy in Fabry Disease Disease thelansis.com

Thelansis knowledge Partners 1 year ago in Business 0

Positive Phase 3 Results for Jazz Pharmaceuticals’ Zepzelca and Tecentriq Combo in ES-SCLC Treatment

Positive Phase 3 Results for Jazz Pharmaceuticals’ Zepzelca and Tecentriq Combo in ES-SCLC Treatment thelansis.com

Thelansis knowledge Partners 1 year ago in Business 0

FDA Grants Orphan Drug Designation to Immuneering’s IMM-1-104 for Pancreatic Cancer Treatment

FDA Grants Orphan Drug Designation to Immuneering’s IMM-1-104 for Pancreatic Cancer Treatment thelansis.com

Thelansis knowledge Partners 1 year ago in Business 0

FDA Grants Rare Pediatric Disease Designation to Papillon Therapeutics’ PPL-001 for Friedreich’s

FDA Grants Rare Pediatric Disease Designation to Papillon Therapeutics’ PPL-001 for Friedreich’s thelansis.com

Thelansis knowledge Partners 1 year ago in Business 0

Nanoscope Therapeutics Prepares BLA Submission for MCO-010 in Retinitis Pigmentosa Following FDA Meeting

Nanoscope Therapeutics Prepares BLA Submission for MCO-010 in Retinitis Pigmentosa Following FDA Meeting thelansis.com

Thelansis knowledge Partners 1 year ago in Business 0